Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc > DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWED
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(80)
•••
Comment by bingostaron Jan 08, 2016 8:30pm
89 Views
Post# 24442263

RE:RE:RE:RE:RE:RE:DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWED

RE:RE:RE:RE:RE:RE:DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWEDThe value of the preferred is the fair value resulting from the negotiation at $1 034 730,they are not trade in the market, but in order for ordinary shares to access any liquidation dividend you need to get rid of those 5M$ of value before receiving any dividend that why is a substantial gain here. It is accounting 101 my friend , you will see that in the financial statements.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities